• Calidi Biotherapeutics posted a net loss of $4.11 million for the quarter ended March 31, 2026, narrowing 19% from a year earlier.
• Operating loss improved 17% to $4.19 million, while total operating expenses fell 17% to $4.19 million.
• Research and development expense rose 7% to $2.59 million, while general and administrative costs dropped 39% to $1.6 million.
• Cash totaled $6.6 million at March 31, 2026, and management said it lacks sufficient cash to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
• Net proceeds of about $5.1 million came from a March 2026 confidentially marketed public offering, and Calidi said it expects to file an IND for a Phase I trial of RedTail lead CLD-401 by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023140), on May 14, 2026, and is solely responsible for the information contained therein.